Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621515 | PMC |
| http://dx.doi.org/10.1038/s41433-024-03358-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Oxidative Stress in Epilepsy-Focus on Melatonin.
Int J Mol Sci
December 2024
Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland.
Oxidative stress develops when there is an excess of oxidants leading to molecular and cellular damage. Seizure activity leads to oxidative stress and the resulting increased lipid peroxidation. Generally, antiseizure medications reduce oxidative stress, although the data on levetiracetam are ambiguous.
View Article and Find Full Text PDFAn Experimental Insight Into the Role of Agomelatine in Renal Ischemia/Reperfusion Injury.
J Biochem Mol Toxicol
December 2024
Department of Physiology, Faculty of Medicine, İnönü University, Malatya, Turkey.
Acute kidney injury (AKI) is one of the leading causes of chronic kidney disease and accounts for 50%-75% of mortality following renal pathologies or organ transplantation. Ischemia‒reperfusion injury (IRI) involves an interrupted blood supply to organs and the kidney; IRI exacerbates AKI development. Owing to several pharmacological treatment methods, AKI still has a poor prognosis, and novel therapeutic options are needed.
View Article and Find Full Text PDFRole of Endoplasmic Reticulum Stress in Melatonin-induced Apoptosis and Inhibition of Invasion and Migration in Adrenocortical Carcinoma Cells.
Discov Med
November 2024
Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
Background: Melatonin, a hormone synthesized by the pineal gland and released into the blood, seems to have anti-tumor properties. However, the mechanisms of the anti-cancer effect of melatonin are largely unknown. This study investigated the anti-tumor activity of melatonin in adrenocortical carcinoma (ACC) and analyzed its molecular mechanisms.
View Article and Find Full Text PDFAntioxidant Therapy in Neonatal Hypoxic Ischemic Encephalopathy: Adjuvant or Future Alternative to Therapeutic Hypothermia?
Metabolites
November 2024
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Article Synopsis
- Oxidative stress-related diseases in newborns are caused by an imbalance between pro-oxidants and antioxidants, affecting both term and preterm infants, and are associated with conditions like hypoxic ischemic encephalopathy (HIE) and retinopathy of prematurity (ROP).
- A comprehensive review of literature from 2012-2024 highlighted various antioxidant therapies—including melatonin and N-acetylcisteine—that have been investigated for their effectiveness in treating these oxidative stress-related diseases in newborns.
- Current findings suggest that therapies like melatonin, allopurinol, and stem cells could serve as potential alternatives to the standard treatment of therapeutic hypothermia for newborns suffering
A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study (MAVRICS).
Hum Vaccin Immunother
December 2024
Department of Translational and Clinical Research, Naval Medical Research Command, Silver Spring, MD, USA.
Vaccine immunogenicity is affected by a variety of factors. Melatonin has been reported to affect immune responses to vaccines and infection. This was a randomized open-label trial - in which adults scheduled to receive the influenza vaccine were randomized to 5 mg melatonin or control to evaluate the effect of post-vaccination melatonin on humoral (hemagglutination-inhibition assays, HAI) and cellular (FluoroSpot) vaccine-specific cytokine responses 14-21 days post-vaccination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!